SFRP2 and glioma: In addition, we found that SFRP2 regulated Wnt/β-catenin activation, and pharmacological inhibition of Wnt/β-catenin signaling by XAV-939 abrogated the effects of SFRP2 knockdown on cancer stemness and radioresistance in glioma.